Antiangiogenic effect of oral 2-methoxyestradiol on choroidal neovascularization in mice

被引：14
作者：
Funakoshi, Taisaku
Birsner, Amy E.
D'Amato, Robert J.
机构：
[1] Harvard Univ, Sch Med, Vasc Biol Program, Childrens Hosp, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA
来源：
EXPERIMENTAL EYE RESEARCH | 2006年 / 83卷 / 05期
关键词：
antiangiogenesis; choroidal neovascularization; 2-methoxyestradiol; age-related macular degeneration; mouse; drug; laser;
D O I：
10.1016/j.exer.2006.05.016
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
We evaluated the efficacy of systemic 2-methoxyestradiol (2ME2) in a laser-induced murime model of choroidal neovascularization (CNV). C57BL/6J mice (8 week old males) were used in this study and divided into four groups. After laser treatment, daily oral treatment with vehicle control, and 30, 50, and 75 mg/kg of 2ME2 was started. Two weeks after laser treatment, digital images of CNV were obtained from fluorescein isothiocyanate-dextran (FITC-dextran) angiography and choroidal flat mount after FITC-dextran perfusion. These images were quantified by NIH image software. Analysis of images from both FITC-dextran angiography and choroidal flat mount with FITC-dextran perfusion demonstrated that the 2ME2 treated groups showed a statistically significant, dose-dependent decrease in CNV. No toxicity or weight loss was observed during the treatment. Significant antiangiogenic effects of oral 2ME2 on laser induced CNV were observed. Since 2ME2 (Panzem (R)) has demonstrated good safety in phase I/II trials for cancer, it has the potential to be used as a novel oral treatment for age-related macular degeneration. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1102 / 1107
页数：6
相关论文
共 26 条
[1]   2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27 [J].
Chauhan, D ;
Li, G ;
Auclair, D ;
Hideshima, T ;
Podar, K ;
Mitsiades, N ;
Mitsiades, C ;
Chen, LB ;
Munshi, N ;
Saxena, S ;
Anderson, KC .
APOPTOSIS, 2004, 9 (02) :149-155
[2]   Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells [J].
Chauhan, D ;
Li, GL ;
Sattler, M ;
Podar, K ;
Mitsiades, C ;
Mitsiades, N ;
Munshi, N ;
Hideshima, T ;
Anderson, KC .
ONCOGENE, 2003, 22 (40) :6296-6300
[3]   Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors [J].
Dahut, WL ;
Lakhani, NJ ;
Gulley, JL ;
Arlen, PM ;
Kohn, EC ;
Kotz, H ;
McNally, D ;
Parr, A ;
Nguyen, D ;
Yang, SX ;
Steinberg, SM ;
Venitz, J ;
Sparreboom, A ;
Figg, WD .
CANCER BIOLOGY & THERAPY, 2006, 5 (01) :22-27
[4]   2-METHOXYESTRADIOL, AN ENDOGENOUS MAMMALIAN METABOLITE, INHIBITS TUBULIN POLYMERIZATION BY INTERACTING AT THE COLCHICINE SITE [J].
DAMATO, RJ ;
LIN, CM ;
FLYNN, E ;
FOLKMAN, J ;
HAMEL, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3964-3968
[5]  
FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
[6]   β-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells [J].
Gökmen-Polar, Y ;
Escuin, D ;
Walls, CD ;
Soule, SE ;
Wang, YF ;
Sanders, KL ;
LaVallee, TM ;
Wang, M ;
Guenther, BD ;
Giannakakou, P ;
Sledge, GW .
CANCER RESEARCH, 2005, 65 (20) :9406-9414
[7]   Pegaptanib for neovascular age-related macular degeneration [J].
Gragoudas, ES ;
Adamis, AP ;
Cunningham, ET ;
Feinsod, M ;
Guyer, DR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2805-2816
[8]  
Heier JS, 2006, OPHTHALMOLOGY, V113, pe1
[9]  
Klauber N, 1997, CANCER RES, V57, P81
[10]   SURGICAL EXCISION OF SUBFOVEAL NEOVASCULAR MEMBRANES IN AGE-RELATED MACULAR DEGENERATION [J].
LAMBERT, HM ;
CAPONE, A ;
AABERG, TM ;
STERNBERG, P ;
MANDELL, BA ;
LOPEZ, PF .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1992, 113 (03) :257-262
123